These molecular alterations activate JAK2 not only in cell lines, expression of these variants in JAK2, MPL, calreticulin and CSF3R in mice also leads to a MPN phenotype suggesting these mutations are potent drivers of MPNs (Jacquelin et al., 2020). This evidence concerns the gene JAK2 and myeloproliferative disorder.